US Patent 9,085,618: What the “Low Acidic Species” Adalimumab Claims Actually Cover and Where the Landscape Breaks

US 9,085,618 is built around a narrow analytical definition of “low acidic species” adalimumab and a linked formulation and therapeutic-use package. The claims do not read like a broad “low charge variants” platform; they read like a product- and process-adjacent specification tied to a particular WCX-10 HPLC method (phosphate/salt mobile phases, pH 7.5 and pH 5.5, 280 nm detection) and a specific “Lys 0” lysine-variant distribution threshold. Claims then layer formulation parameters (pH 5.0-6.5, polysorbate 80, mannitol, histidine buffer options) and TNF-alpha indications.

The claim set has three practical implications for freedom-to-operate (FTO) and for competitive R&D:

The scope is anchored to a defined measurement method and defined compositional cutoffs (<10% total acidic species; <75% Lys variants with zero C-terminal lysines; sometimes tighter numeric windows).
Dependent claims broaden the underlying biological/biophysical sources of “acidic species” (deamidation, glycation, afucosylation, MGO, citric acid; glycosylation and acetonation; fragmentation categories), but they still remain tethered to the analytical definition.
Formulation and dosing are secondary but still add enforceable structure; therapeutic use claims then capture any administration of the claimed composition for TNF-alpha disorders.

What are the independent claim anchors?

Claim 1: the core analytical composition definition

Claim 1 defines a “low acidic species composition” of adalimumab with four main anchors:

Total acidic species threshold: “less than 10% total acidic species of adalimumab.”
Lysine variant constraint: “less than 75% of the lysine variant species … have zero C-terminal lysines (Lys 0).”
Analytical quantification method: acidic species are “quantified based on the relative area percent of peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram.”
Method specification:
- First mobile phase: 10 mM sodium phosphate dibasic (pH 7.5)
- Second mobile phase: 10 mM sodium phosphate dibasic, 500 mM sodium chloride (pH 5.5)
- Detection: 280 nm

This claim is not simply about “charge variants” in general. It is about a specific chromatographic relative-area method and an explicitly defined “earlier-than-main-peak” peak set.

Claim 18: expansion that removes explicit “process-related impurities”

Claim 18 defines a similar “low acidic species composition,” adding two major layers:

Net negative charge requirement: “acidic species … have a net negative charge relative to the adalimumab main species.”
Exclusion of process-related impurities: acidic species “do not include process-related impurities selected from host cell proteins, host cell nucleic acids, chromatographic materials and media components.”
Broader acidic species taxonomy: explicitly enumerates acidic species categories:
- charge variants: deamidation, glycation, afucosylation, MGO, citric acid
- structure variants: glycosylation, acetonation
- fragmentation variants: Fab fragments, C-terminal truncations, missing heavy chain variable domain variants

Claim 18 still retains the same WCX-10 HPLC method details and the Lys 0 / total acidic species thresholds (less than 10% total acidic species; <75% Lys 0 fraction).

Claim 25: formulation + dosing + method coupling

Claim 25 is a pharmaceutical composition claim that tightly couples:

Amount: “25-100 mg of a low acidic species adalimumab composition”
Same compositional constraints:
- <10% total acidic species
- <75% of lysine variant species have Lys 0
Same analytical method: WCX-10 HPLC relative area percent of peaks eluting earlier than main peak; mobile phases and 280 nm detection
Formulation window: pH between 5.0 and 6.5

Claim 25 also inserts an additional structure element: “and a buffering agent, wherein the pH … is between 5.0 to 6.5.”

How do the dependent claims sharpen scope and enforcement leverage?

Numeric narrowing series (acidic species)

The dependent claims introduce multiple overlapping windows that create distinct infringement “bands”:

Claim	Acidic species limitation
5	≤ 9% total acidic species
6	1.4% to 9%
7	≤ 8%
8	≤ 7%
22	≤ 8% (composition produced in mammalian host cell in claim 21)
26	1.4% to 9% (pharmaceutical composition)
27	≤ 8% (pharmaceutical composition)

In enforcement terms, the broadest compositions (<10%) are covered by claim 1 and claim 18; the tighter windows (≤9, 1.4-9, ≤8, ≤7) create additional dependent hooks that may be easier to prove with certain product release profiles.

Host cell and manufacturing category

Claims 3 and 21 require adalimumab “produced in a mammalian host cell grown in cell culture.” Dependent claim 4 narrows host cell selection to:

CHO cell
NSO cell
COS cell
SP2 cell

This is not a “process claims” structure (no steps are recited), but it restricts eligible embodiments to certain mammalian cell contexts and supports an argument that competitor products made in other systems could avoid coverage if they cannot meet the claim’s explicit host-cell limitation.

AR1 and AR2 dependent claim

Claim 2 adds “first acidic region (AR1) and second acidic region (AR2).” The claim text does not define AR1/AR2 boundaries in the excerpt, but its inclusion indicates that the patent is concerned with the distribution across chromatographic regions, not only a total early-eluting area metric.

Pharmaceutical excipient and buffer embodiments

Claims 12-17 and claim 24 specify formulation excipient classes. Key enumerations:

Buffering agent, surfactant, polyol (claim 13)
Surfactant: polysorbate 80 (claim 14)
Amino acid buffering agent: histidine (claims 15-16)
Polyol: mannitol (claim 17)

These dependent claims materially constrain the “carrier” side of infringement. Competitors that omit polysorbate 80 or mannitol, or use different buffer systems, may still be able to fall outside certain dependent claim coverage, while still potentially implicating broader claims where excipient selection is not limited.

Therapeutic use coverage

Claim 28 covers TNF-alpha detrimental disorders with the administered product of claim 9. Claim 29 enumerates the indication list:

rheumatoid arthritis
juvenile idiopathic arthritis
psoriatic arthritis
ankylosing spondylitis
Crohn’s Disease
ulcerative colitis
plaque psoriasis
hidradenitis suppurativa (HS)
uveitis
active axial spondyloarthritis (active axSpA)
non-radiographic axial spondyloarthritis (nr-axSpA)

Claim 30 mirrors claim 28 for administration of claim 25. This dual structure matters: it allows infringement theories either off the “carrier/formulation” claim set in claim 9/25 or off the composition measurement anchors.

Claim-to-competitive product mapping: what a challenger would have to prove

Infringement generally turns on the measurement method

Because acidic species are quantified using the WCX-10 HPLC relative area of peaks eluting earlier than the main peak, the patent is set up for a measurement-based infringement contest rather than a purely structural one.

Competitors attempting design-around would target at least one of:

failing the <10% total acidic species metric
failing the <75% Lys 0 lysine-variant metric
producing a chromatogram that is not produced using the claimed WCX-10 method conditions (mobile phases and pH) and/or detection at 280 nm
shifting the “main peak” definition or altering the peak set that qualifies as “earlier than the main peak” (depending on how “main peak” is defined in evidence, even without explicit claim definition)

Because the claim explicitly recites mobile-phase identity, pH values, salt concentration, and detection wavelength, a competitor can attempt to avoid literal scope by using a different method. In practice, however, litigation often turns on whether the methods are functionally equivalent and whether an accused product’s release analytics correspond to the claimed analytical framework.

What “acidic species” are in the claim’s worldview

Claim 18 gives the strongest taxonomy of the acidic species types covered:

charge variants: deamidation, glycation, afucosylation, MGO, citric acid
structure variants: glycosylation, acetonation
fragmentation variants: Fab fragment variants, C-terminal truncation variants, variants missing a heavy chain variable domain

This matters because competitors might argue that their acidic species are “impurities” or come from different origins. The patent directly attempts to preempt part of that argument by excluding “process-related impurities” from the acidic species categories.

Lysine variant and Lys 0 constraint drives a distinct mechanistic axis

The Lys 0 constraint is a specific attribute not always present in generic charge variant disclosures for monoclonal antibodies. It can capture a product that has reduced C-terminal lysine processing variants. A competitor can meet the “low acidic species” metric yet still fail due to a higher Lys 0 fraction, or vice versa.

In business terms: the patent is enforcing not just “less acidic,” but “less acidic with a specific lysine-variant profile.”

Patent landscape: how US 9,085,618 fits into typical adalimumab life-cycle claims

How this claim style compares to common antibody formulation and variant patents

US 9,085,618 uses three familiar life-cycle claim archetypes:

Analytics-linked product specification
- QC chromatogram method recited (WCX-10), numeric cutoffs, and earlier-than-main-peak logic.
Variant-category scaffolding
- enumerated charge/structure/fragment classes tied to acidic species.
Formulation and medical-use linkage
- pH window; excipient selection (polysorbate 80, histidine buffer, mannitol); TNF-alpha disorder administration.

For an investor or licensing team, the enforceability risk profile usually depends on prior art showing that:

the WCX-10 approach and mobile phase choices were known and used to define acidic species/charge variants for monoclonal antibodies, including adalimumab or close comparators; and
low-acidic adalimumab lots were previously described with corresponding thresholds; and
Lys 0 distributions and their relationship to charge variants were known.

Because the claim is unusually specific about the chromatography setup and quantification rule, the patent can withstand some prior-art pressure where prior art uses different chromatographic systems or different quantification conventions.

What prior art most often attacks in this space

In antibody variant patents, challenges typically use:

Method substitution: prior art defines acidic species using IEX or WCX under different salt gradient, pH, column chemistry, or detection; challengers argue that the claim’s specificity limits novelty to a method.
Threshold obviousness: prior art may disclose “reduced acidic species” without selecting the claimed cutoffs (<10%, ≤9, ≤8, ≤7, 1.4-9) and without the Lys 0 constraint; challengers argue that selecting a lower range would be routine.
Analytical reproducibility disputes: opponents attempt to show variability in peak integration and assignment of “main peak,” undermining that the claimed criteria correspond to a reproducible product property.
Product class substitution: prior art may cover “low charge variants” or “low aggregates” and the challenger argues that “acidic species” is an expected correlation.

US 9,085,618 anticipates part of the “broad low variants” argument by enumerating how acidic species are measured and by adding the Lys 0 constraint.

Critical reading of claim breadth: what is covered and what is not

Covered

Adalimumab compositions with:
- <10% total acidic species (claim 1 and claim 18)
- <75% Lys variants with Lys 0 (claims 1/18 and also in claim 25)
- acidic species quantified by the specified WCX-10 HPLC rule
Taxonomy of acidic species types in claim 18: deamidation, glycation, afucosylation, MGO, citric acid, glycosylation, acetonation, Fab fragments, C-terminal truncations, missing VH domain fragments
Mammalian host cell production in certain cell lines (CHO, NSO, COS, SP2) (claims 3-4)
Pharmaceutical formulations with:
- pH 5.0-6.5 (claims 11 and 25)
- excipient options including polysorbate 80, histidine buffer, mannitol (claims 13-17 and claim 24)
TNF-alpha detrimental disorder treatment indications listed in claim 29

Not cleanly covered (from the claim text)

Adalimumab made in non-specified host cells if the competitor cannot satisfy the claim 4 cell line limitation in dependent claims (though independent claims 1/18 do not require the specific cell line).
Products where the acidic species metric is not established by the claimed WCX-10 method and 280 nm detection with the specified phosphate/salt mobile phases.
Products where Lys 0 fraction is ≥75% of lysine variants in the relevant lysine variant distribution.

Landscape risk and licensing posture: how companies typically position around this kind of claim

Key diligence checklist for an accused product

An FTO memo or licensing review for a biologic competitor should map each release metric to the claim terms:

WCX-10 parameters:
- phosphate dibasic concentrations and pH 7.5 first phase
- 10 mM phosphate dibasic + 500 mM NaCl pH 5.5 second phase
- detection at 280 nm
Integration logic:
- relative area percent of peaks eluting earlier than the main peak
Acceptance:
- <10% total acidic species
- <75% lysine variants have Lys 0
Formulation:
- pH between 5.0-6.5
- whether polysorbate 80 / histidine / mannitol are present (depending on which dependent claim is asserted)
Indication:
- whether marketed/used within the claim 29 TNF-alpha list

Key design-around levers

Because the patent is analytical-method sensitive, the most direct design-around levers are:

alter the analytical method used to set product acceptance (not always possible because release QC must still be comparable)
adjust the product itself to shift:
- total acidic species above 10% or to fall outside the narrower dependent windows
- Lys 0 distribution to exceed 75%
avoid dependent formulation embodiments by changing buffer/surfactant/polyol selection, though core claims still require the composition itself

Key Takeaways

US 9,085,618 is a measurement-anchored “low acidic species” adalimumab patent with enforceable thresholds (<10% total acidic species; <75% Lys 0 fraction) and an explicit WCX-10 HPLC method (phosphate dibasic mobile phases at pH 7.5 and pH 5.5, 500 mM NaCl second phase, 280 nm detection) plus a quantification rule (relative area percent of peaks eluting earlier than the main peak).
Claim scope expands through dependent claims that enumerate acidic species classes (deamidation, glycation, afucosylation, MGO, citric acid, glycosylation, acetonation, Fab fragments, C-terminal truncation, missing VH domain) and through formulation limitations (pH 5.0-6.5; optional polysorbate 80, histidine, mannitol).
Therapeutic use claims cover a broad TNF-alpha disorder set; infringement theories can attach both to composition/formulation and to medical use for those indications.
Competitive risk concentrates on whether a candidate product’s WCX-10 acidic species and Lys 0 profile meet the claimed cutoffs under the stated method conditions; formulation changes can help with dependent claims but not the core compositional measurement requirements.

FAQs

What does “acidic species quantified based on peaks eluting earlier than the main peak” mean for infringement?
It ties infringement to the chromatographic integration rule: the patent defines acidic species as the relative area percent of earlier-than-main-peak peaks in a specified WCX-10 HPLC run with 280 nm detection.
Does the patent cover all adalimumab low-charge variants?
No. The claims restrict coverage to low acidic species meeting specific thresholds and a specific WCX-10 HPLC quantification scheme, plus a Lys 0 lysine-variant distribution constraint.
How do the Lys 0 limits change the risk profile versus “low acidic species” alone?
A product can meet the low acidic species threshold yet still infringe only if it also has <75% of lysine variants with zero C-terminal lysines (Lys 0). Lys 0 acts as a second gate.
Which formulation components matter most?
pH 5.0-6.5 is central (independent pharmaceutical claim structure in claim 25, and claim 11 for claim 9). Polysorbate 80, histidine buffer, and mannitol are in dependent embodiments (claims 14, 16, 17, and claim 24) and can matter depending on which claim is asserted.
Do the therapeutic claims depend on where the adalimumab came from (host cell type)?
The therapeutic use claims depend on the pharmaceutical composition claims they incorporate (claim 9 or claim 25). Host-cell limitations appear in composition-dependent claims (claims 3-4 and 21), so the relevance depends on the asserted claim chain.

References

[1] US Patent 9,085,618, claims 1-30 (provided by user text).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	9,085,618	2033-11-12
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	9,085,618	2033-11-12
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	9,085,618	2033-11-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
United States of America	9522953	⤷ Start Trial
United States of America	9315574	⤷ Start Trial
United States of America	9266949	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 9,085,618

Summary for Patent: 9,085,618